Skip to main content
Top
Published in: Diabetologia 3/2004

01-03-2004 | Short Communication

Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes

Authors: A. S. F. Doney, B. Fischer, J. E. Cecil, K. Boylan, F. E. McGuigan, S. H. Ralston, A. D. Morris, C. N. A. Palmer, PhD

Published in: Diabetologia | Issue 3/2004

Login to get access

Abstract

Aims/hypothesis

The Pro12Ala polymorphism of peroxisome proliferator-activated receptor (PPAR)γ has been consistently associated with Type 2 diabetes. The rare Ala12 variant is estimated to reduce the risk of developing Type 2 diabetes by 20 percent. This variant is in linkage disequilibrium with another common variant, T1431. Both have opposing associations with body weight. We therefore examined the association of specific haplotypes marked by these two variants with susceptibility to Type 2 diabetes.

Methods

We determined the PPARG genotype of a large Scottish cohort of Type 2 diabetic patients (n=1997) and compared allele frequencies with a cohort of local children (n=2444) and a middle-aged, population-based cohort from Scotland (n=1061).

Results

Frequency of the Ala12 allele was slightly lower in the Type 2 diabetic cohort than in the children [odds ratio (OR)=0.91, p=0.1]. In contrast, the Ala12 variant was under-represented in the Type 2 diabetic population when compared with similarly aged non-diabetic adults (OR=0.74, p=0.0006). When the Ala12 variant was on a haplotype not bearing the 1431T variant, it conferred greater protection (OR=0.66, p=0.003). However, when it was present in haplotypes containing the 1431T variant (70% of Ala12 carriers), this protection was absent (OR=0.99, p=0.94).

Conclusions/interpretation

We replicated the finding that the Ala12 variant of PPARγ affords protection from Type 2 diabetes, and suggest that this protection is modulated by additional common variation at the PPARG locus.
Literature
1.
go back to reference Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed Deeb SS, Fajas L, Nemoto M, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287CrossRefPubMed
2.
go back to reference Luan J, Browne PO, Harding AH et al. (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686–689CrossRefPubMed Luan J, Browne PO, Harding AH et al. (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686–689CrossRefPubMed
3.
go back to reference Doney A, Fischer B, Frew D et al. (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21CrossRefPubMedPubMedCentral Doney A, Fischer B, Frew D et al. (2002) Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet 3:21CrossRefPubMedPubMedCentral
4.
go back to reference Morris AD, Boyle DI, MacAlpine R et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528CrossRefPubMedPubMedCentral Morris AD, Boyle DI, MacAlpine R et al. (1997) The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ 315:524–528CrossRefPubMedPubMedCentral
5.
go back to reference McGuigan FE, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH (2001) Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12:91–96CrossRefPubMed McGuigan FE, Armbrecht G, Smith R, Felsenberg D, Reid DM, Ralston SH (2001) Prediction of osteoporotic fractures by bone densitometry and COLIA1 genotyping: a prospective, population-based study in men and women. Osteoporos Int 12:91–96CrossRefPubMed
6.
go back to reference Ek J, Andersen G, Urhammer SA et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176CrossRefPubMed Ek J, Andersen G, Urhammer SA et al. (2001) Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44:1170–1176CrossRefPubMed
7.
8.
go back to reference Ridker PM, Cook NR, Cheng S et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859–863CrossRefPubMedPubMedCentral Ridker PM, Cook NR, Cheng S et al. (2003) Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 23:859–863CrossRefPubMedPubMedCentral
9.
go back to reference Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21:1657–1662CrossRefPubMed Ostgren CJ, Lindblad U, Melander O, Melander A, Groop L, Rastam L (2003) Peroxisome proliferator-activated receptor-gammaPro12Ala polymorphism and the association with blood pressure in type 2 diabetes: Skaraborg Hypertension and Diabetes Project. J Hypertens 21:1657–1662CrossRefPubMed
10.
go back to reference Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21:1649–1655CrossRefPubMed Rodriguez-Esparragon FJ, Rodriguez-Perez JC, Macias-Reyes A, Alamo-Santana F (2003) Peroxisome proliferator-activated receptor-gamma2-Pro12Ala and endothelial nitric oxide synthase-4a/bgene polymorphisms are associated with essential hypertension. J Hypertens 21:1649–1655CrossRefPubMed
Metadata
Title
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
Authors
A. S. F. Doney
B. Fischer
J. E. Cecil
K. Boylan
F. E. McGuigan
S. H. Ralston
A. D. Morris
C. N. A. Palmer, PhD
Publication date
01-03-2004
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1323-1

Other articles of this Issue 3/2004

Diabetologia 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.